Neurala In The News

Media and company announcements

Featured

Neurala Biosciences

February 24, 2026

Neurala Announces Appointment of Spyros Papapetropoulos, MD, PhD, as Board Chair

February 11, 2026

Neurala Biosciences Reports Phase 1 Data Supporting Advancement of Second-Generation DMT–Harmala Candidates NBX-100 and NBX-200

Nature, Scientific Reports

December 2, 2025

Scientific Reports Publishes World-First Clinical Data on Neurala’s Precision DMT–Harmala Platform

Other Coverage

December 5, 2025

University of Melbourne Announces Neurala’s Development of Novel Therapeutic Psychedelic

December 12, 2024

Largest-ever survey on ayahuasca highlights links to better mental health and wellbeing

Melbourne University

Innovative research translation and commercialisation accelerated through funding boost

November 17, 2023

University of Melbourne mental health startup using psychedelics kicks off with $4.5 million

November 13, 2023

Melbourne University

University of Melbourne unveils six start ups, announces $4.5M investment in company developing psychedelic-assisted therapies

November 14, 2023

BioSpectrum Asia

Australian startup Psychae Therapeutics secures $4.5 M for developing psychedelic-assisted therapies for mental healthcare

November 22, 2023

Forbes Australia

Betting on botanicals: Australian DMT research scores $4.5 million